CDC Assay Complement Addition to Reduce Nonspecific Cytotoxicity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

CDC assays exhibit variability due to non-specific cytotoxicity caused by slow complement addition, leading to undesirable assay results.

Innovation Solution

Increase the speed of complement addition in CDC assays to at least 250 μL/s, or add complement to the assay plate before adding target cells, to reduce non-specific cytotoxicity and variability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If complement is added slowly to target cells in CDC assays, then the assay procedure is easier to control, but non-specific cytotoxicity increases causing assay variability

Engineering Contradiction:

Improveassay precisionVSAvoidnon-specific cytotoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary anti-action by pre-absorbing complement onto target cells for 20 minutes before adding the test antibody. This pre-treatment neutralizes complement components that would otherwise cause non-specific cytotoxicity when added slowly during the assay, thereby improving reliability without requiring slow addition protocols

Inventive Principle:

Principle #9Preliminary anti-action

Solution Approach 2:

The patent changes the parameter of complement addition from slow gradual addition to rapid addition (or pre-addition). By altering the timing and speed parameters of complement introduction, the method eliminates the trade-off between ease of control and non-specific cytotoxicity, achieving both reliability and reduced harmful effects

Inventive Principle:

Principle #35Parameter changes

2Measurement precision

If complement is added rapidly to target cells in CDC assays, then non-specific cytotoxicity is reduced improving assay precision, but the procedure becomes more difficult to control

Engineering Contradiction:

Improveassay variabilityVSAvoidcomplement addition control

Core Design Contradiction:

Measurement precisionVSEase of operation

Solution Approach 1:

The patent applies preliminary action by adding complement to the assay plate before adding target cells, or by pre-absorbing complement onto cells for 20 minutes. This advance preparation allows the complement to be distributed evenly and stabilized, enabling rapid subsequent addition without loss of control, thus achieving both precision and ease of operation

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent inverts the conventional sequence by adding complement before target cells rather than after. This reversal of the addition sequence fundamentally changes the dynamics of the assay, allowing rapid complement introduction while maintaining ease of control through the inverted procedural approach

Inventive Principle:

Principle #13The other way round (Inversion)

Data Source

PatentUS20250258161A1Complement-dependent cytotoxicity methods

Publication Date: 2025.08.14 AMGEN INC

AI summary

The present invention relates to complement-dependent cytotoxicity assays and methods of addition of complement to cells.